Change of antiretroviral therapy in HIV-infected patients;Cambio del tratamiento antirretroviral en el paciente VIH

Farmacia Hospitalaria

Volumn 28, Issue 6 SUPPL. 1, 2004, Pages 48-54

  Pedreira Vázquezo, Isaura ^a   Margusino Framinan L ^a   Perez Fernandez K ^a   Martin Herranz I ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Modification; Simplification; Therapeutic failure; Toxicity; Virologic failure

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; ARTICLE; DRUG HYPERSENSITIVITY; ERECTILE DYSFUNCTION; HAIR LOSS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; LEUKOCYTE COUNT; LIPODYSTROPHY; MAJOR CLINICAL STUDY; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 14644401836     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ensoli F, Sirianni MC. HIV/HCV co-infection: clinical and therapeutic challenges. AIDS 2002; 16 (10): 1419-20.
2. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med 2003; 138 (3): 197-207.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clinical Infectious Diseases 2002; 34: 831-7.
4. Directrices para el empleo de fármacos antirretrovirales en adultos y adolescentes VIH+ elaboradas por la Comisión sobre Prácticas Clínicas para el Tratamiento de la Infección por VIH perteneciente al Departamento de Salud y Servicios Humanos de Estados Unidos (DHHS) y la fundación Henry J. Kaiser Family. Febrero 2002. Disponible en http://bidsinfo.nih.gov/guidelines/adult/archive/AA020402.pdf.
5. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Disponible en http://www.msc.es/profesional/preProSalud/sida/pdfs/Tarv2002.pdf.
6. Soriano V. Sequencing antiretroviral drugs. AIDS 2001; 15 (5): 547-51.
7. Riera M, Ribas MA, Pérez MJ, Mallolas J, Portilla J, Viciana P, et al. Approach to treatment of patients with virologic failure to multiple regimens. Enferm Infecc Microbiol Clin 2002; 20 (Supl. 2): 58-67.
8. Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000; 14 (11): 1545-52.
9. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Swiss HIV Cohort Study. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358: 1322-7.
10. Girard PM, Guiguet M, Bollens D, Goderel I, Meyohas MC, Lecomte I, et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. Clin Infect Dis 2000; 31 (4): 987-94.
11. Mocroft A, Youle M, Moore A, Sabin CA, Madge S, Cozzi Lepri A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15 (2): 185-94.
12. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999; 179 (4): 790-8.
13. Youle M, Sawyer W for the HIV Health Economics Collaboration. Reasons for discontinuation of antiretroviral treatment: a clinical survey (letter). AIDS 1998; 12: 186.
14. Weidle PJ, Lichtenstein KA, Moorman AC, Von Bargen JC, Greenberg KS, Palella Jr FJ, et al. Factors associated with the successful modification of antiretroviral therapy. HIV Outpatient Study Investigators. AIDS 2000; 14 (5): 491-7.
15. Recomendaciones de la Comisión sobre Prácticas Clínicas para el Tratamiento de la Infección por VIH del Departamento de Salud y Servicios Humanos de Estados Unidos (DHHS) y la fundación Henry J. Kaiser Family de Junio de 2003. Disponible en http://aidsinfo.nih.gov/guidelines/adult/archive/AA_071403.pdf.
16. Gulick R. When to switch and what to switch to: strategic use of antiretroviral therapy. AIDS Read; 10 (3): 156-61; discussion 171-4.
17. Murphy RL, Smith WJ. Switch studies: a review. HIV Med 2002; 3 (2): 146-55.
18. Ribera E, Aguirrebengoa K, Miralles C, Antela A, Rivero A, Arribas JR, et al. Simplification of antiretroviral treatment. Enferm Infecc Microbiol Clin 2002; 20 (Supl. 2): 48-57.
19. Barreiro P, Garcia-Benayas T, Soriano V, Gallant J. Simplification of antiretroviral treatment-how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002; 4 (4): 233-41.
20. van Roon EN, Verzijl JM, Juttmann JR, Lenderink AW, Blans MJ, Egberts AC, et al. Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20 (3): 290-4.
21. d'Arminio A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. ICONA Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14 (5): 499-507.
22. Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, Youle M, et al. Naively changing HAART. HIV Med 2002; 3 (4): 254-62.
23. Proctor VE, Tesfa A, Tompkins DC. Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS 1999; 13 (9): 535-44.
24. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17 (4): 169-77.
25. Escobar I, Campo M, Martín J, Fernández-Shaw C, Pulido F, Rubio R, et al. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003; 37 (6): 775-81.
26. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003; 101 (4): 797-810.
27. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29 (5): 484-94.